ISRG

Intuitive Surgical

$393.38

+3.85%
Aug 10, 2026
Bobby Quantitative Model
Intuitive Surgical Inc. is a global leader in robotic-assisted minimally invasive surgery, primarily known for its da Vinci surgical systems, along with the instruments, accessories, and services that support them. The company has placed over 10,000 da Vinci systems worldwide, with a dominant market share in the U.S. and expanding presence in emerging markets, making it the undisputed market leader in surgical robotics. Currently, the stock is under pressure due to management's decision not to raise full-year guidance after a strong Q2, signaling potential growth deceleration, while also facing regulatory scrutiny over a stapler safety concern and increasing competition from Medtronic's Hugo robot. Despite these headwinds, the company's entrenched market position and ongoing innovation continue to drive long-term investor interest.

People also watch

Becton Dickinson

Becton Dickinson

BDX

Analysis
Modernland Realty Ltd

Modernland Realty Ltd

MDLN

Analysis
West Pharmaceutical Services (United States)

West Pharmaceutical Services (United States)

WST

Analysis
Hologic

Hologic

HOLX

Analysis
The Cooper Companies

The Cooper Companies

COO

Analysis

ISRG 12-Month Price Forecast

Historical Price
Current Price $393.38
Average Target $393.38
High Target $452.39
Low Target $334.37

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $477.25 and implied upside of +21.3% versus the current price.

Average Target

$477.25

0 analysts

Implied Upside

+21.3%

vs. current price

Analyst Count

covering this stock

Price Range

$324 - $685

Analyst target range

The target price range spans from a low of $324.00 to a high of $685.00, representing a wide spread of 111% between the low and high, which signals high uncertainty about the company's future performance. The high target of $685 implies a 83.3% upside, likely assuming successful expansion of the da Vinci system into new procedures and geographies, while the low target of $324 suggests a 13.3% downside, possibly pricing in competitive threats from Medtronic and regulatory issues. Recent ratings have been stable, with no major upgrades or downgrades, but the wide range indicates that analysts have divergent views on the stock's growth prospects.

Drowning in data?

Find the real signal!

ISRG Technical Analysis

ISRG is in a clear downtrend, with the stock price falling 21.2% over the past year and 33.5% year-to-date. The current price of $373.71 sits at 13.7% above the 52-week low of $328.57 but is 38.1% below the 52-week high of $603.88, indicating that the stock is trading near the lower end of its range, which could signal a value opportunity or a falling knife. The 1-year price change of -21.2% contrasts sharply with the S&P 500's +21.5% gain, highlighting significant underperformance and a persistent downtrend.

Beta

1.46

1.46x market volatility

Max Drawdown

-44.0%

Largest decline past year

52-Week Range

$329-$604

Price range past year

Annual Return

-16.3%

Cumulative gain past year

PeriodISRG ReturnS&P 500
1m-3.3%+2.4%
3m-8.9%+4.7%
6m-20.7%+11.7%
1y-16.3%+21.3%
ytd-30.0%+13.4%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

ISRG Fundamental Analysis

ISRG's revenue growth remains robust, with Q1 2026 revenue of $2.77 billion, up 22.96% year-over-year, and a clear acceleration from the 13.6% growth in Q1 2025. The company's revenue mix is diversified, with Instruments and Accessories contributing $1.69 billion (61% of total), Services $434 million, and Systems $651 million, showing strong recurring revenue streams. However, the growth trajectory may be slowing, as management's decision not to raise full-year guidance after Q2 suggests a potential deceleration in the coming quarters.

Quarterly Revenue

$2.8B

2026-03

Revenue YoY Growth

+23.0%

YoY Comparison

Gross Margin

66.1%

Latest Quarter

Free Cash Flow

$2.8B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Instruments and Accessories
Services
Systems

Open an Account, get $2 TSLA now!

Valuation Analysis: Is ISRG Overvalued?

Given ISRG's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 70.8x, while the forward PE is 31.0x, implying that the market expects significant earnings growth, with a PEG ratio of 3.17. This wide gap between trailing and forward PE suggests that the market is pricing in a substantial acceleration in earnings, which may be optimistic given the recent guidance concerns.

PE

70.8x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 49x~85x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

49.9x

Enterprise Value Multiple